CompletedNCT01822418
Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)
Medication studyAges 18–60Germany
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- MannheimSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJanuary 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 27
- Sponsor
- Central Institute of Mental Health, Mannheim
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Germany
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT01822418
- Official title
Show the full official title
Agomelatine Treatment of Major Depressive Episodes in the Course of Schizophrenic Psychoses (AGOPSYCH)
Recruitment & locations
CompletedMannheim
Questions about this study
Who is behind this study?
The study sponsor is Central Institute of Mental Health, Mannheim, a research institute.
Did this study involve medication?
Yes. The study involved medication, including agomelatine.
Who was this study for?
Listed age limits: 18 years to 60 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
Effects of intranasal application of oxytocin on empathy and mentalising in patients with psychotic disorders and severe personality disorders
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants